MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
27.80
-3.28
-10.55%
After Hours: 28.18 +0.38 +1.37% 19:34 05/14 EDT
OPEN
31.30
PREV CLOSE
31.08
HIGH
31.64
LOW
27.54
VOLUME
4.19M
TURNOVER
--
52 WEEK HIGH
60.87
52 WEEK LOW
27.54
MARKET CAP
5.12B
P/E (TTM)
-28.7160
1D
5D
1M
3M
1Y
5Y
1D
Legend Biotech Price Target Maintained With a $55.00/Share by Cantor Fitzgerald
Dow Jones · 9h ago
Cantor Fitzgerald Reiterates Overweight on Legend Biotech, Maintains $55 Price Target
Benzinga · 10h ago
BUZZ-Legend Biotech slips after brokerages cut PT
Reuters · 10h ago
Legend Biotech Secures New Headquarters in Bridgewater
TipRanks · 11h ago
Legend Biotech price target lowered to $71 from $88 at Truist
TipRanks · 11h ago
Legend Biotech’s Carvykti: Strong Growth Prospects and Strategic Expansion Justify Buy Rating
TipRanks · 12h ago
Scotiabank Reaffirms Their Buy Rating on Legend Biotech (LEGN)
TipRanks · 12h ago
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Artiva Biotherapeutics, Inc. (ARTV) and Astria Therapeutics (ATXS)
TipRanks · 13h ago
More
About LEGN
More
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Recently
Symbol
Price
%Change

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.